Here's what CNBC's "Fast Money" traders had to say about some of the market's biggest movers on their "Pops and Drops" segment Monday.
More from Investing
Sarepta Craters After FDA Rejection of Muscular Dystrophy Drug
In its rejection of golodirsen, Sarepta's second treatment for Duchenne muscular dystrophy, the FDA cites concerns over infection risk "related to intravenous infusion ports and renal toxicity," the company said in a statement.
Baidu Stock Continues Bull Run as Trade Optimism, Strong Earnings Spark Surge
The Chinese tech giant is charging hard to close August, adding hope for bulls betting on an inflection point.
Jim Cramer: Hail to Estee Lauder, the New England Patriots of Retail
Under CEO Fabrizio Freda, the cosmetics giant takes risks and then does the blocking and tackling needed to win in a challenging retail environment.
It's 'Game On' for Silver; Explosion Could Come Soon
Silver could see $20 an ounce by year-end.
Apple Arcade Could Be a Big Hit, But Its Value Won't Be Realized Overnight
A low price point plus one-month free trial could make Apple Arcade an appealing option for millions of gamers worldwide. But old habits could still prove hard to break.